Effect of intensive glycaemic control on endothelial progenitor cells in patients with long-standing uncontrolled type 2 diabetes

European Journal of Preventive Cardiology

Volumn 21, Issue 9, 2014, Pages 1153-1162

  Lev, Eli I ^a   Singer, Joel ^b   Leshem Lev, Dorit ^a   Rigler, Merav ^b   Dadush, Oshrat ^a   Vaduganathan, Muthiah ^c   Battler, Alexander ^a   Kornowski, Ran ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Diabetes; endothelial progenitor cells; glycaemic control

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; HEMOGLOBIN A1C; VASCULOTROPIN RECEPTOR 2; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; NITRIC OXIDE; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LONG ACTING INSULIN; METFORMIN; SHORT ACTING INSULIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; ARTICLE; CELL CULTURE; CELL MIGRATION; CELL VIABILITY; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; FEMALE; FLOW CYTOMETRY; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGED; APOPTOSIS; BLOOD; CYTOLOGY; DIABETES MELLITUS, TYPE 2; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; METABOLISM; PHYSIOLOGY; VASCULAR ENDOTHELIUM; YOUNG ADULT; BLOOD GLUCOSE MONITORING; CELL COUNT; CELL DAMAGE; CELL FUNCTION; COMPARATIVE STUDY; DIABETIC DIET; DISEASE DURATION; DOWN REGULATION; HEMOGLOBIN BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

ADULT; AGED; APOPTOSIS; BLOOD GLUCOSE; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; ENDOTHELIAL PROGENITOR CELLS; ENDOTHELIUM, VASCULAR; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NITRIC OXIDE; YOUNG ADULT;

EID: 84906548654     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487313488300     Document Type: Article

References (41)

1. Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005 ; 28: 2130-2135
2. Urbich C, Dimmeler S. Endothelial progenitor cells characterization and role in vascular biology. Circ Res. 2004 ; 95: 343-353
3. Hristov M, Zernecke A, Liehn EA, et al. Regulation of endothelial progenitor cell homing after arterial injury. Thromb Haemost. 2007 ; 98: 274-277
4. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002 ; 105: 3017-3024
5. Werner N, Priller J, Laufs U, et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol. 2002 ; 22: 1567-1572
6. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000 ; 95: 952-958
7. Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med. 2004 ; 8: 498-508
8. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999 ; 85: 221-228
9. Gehling UM, Ergün S, Schumacher U, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood. 2000 ; 95: 3106-3112
10. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001 ; 89: E1 - E7
11. Eizawa T, Ikeda U, Murakami Y, et al. Decrease in circulating endothelial progenitor cells in patients with stable coronary artery disease. Heart. 2004 ; 90: 685-686
12. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003 ; 348: 593-600
13. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005 ; 353: 999-1007
14. Fadini GP, Boscaro E, de Kreutzenberg S, et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care. 2010 ; 33: 1097-1102
15. Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005 ; 45: 1449-1457
16. Fadini GP, Sartore S, Albiero M, et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol. 2006 ; 26: 2140-2146
17. Egan CG, Lavery R, Caporali F, et al. Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia. 2008 ; 51: 1296-1305
18. Liao YF, Chen LL, Zeng TS, et al. Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes. Vasc Med. 2010 ; 15: 279-285
19. Tepper OM, Galiano RD, Capla JM, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002 ; 106: 2781-2786
20. Caballero S, Sengupta N, Afzal A, et al. Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes. 2007 ; 56: 960-967
21. De Falco E, Avitabile D, Totta P, et al. Altered SDF-1-mediated differentiation of bone marrow-derived endothelial progenitor cells in diabetes mellitus. J Cell Mol Med. 2009 ; 13: 3405-3414
22. Sorrentino SA, Bahlmann FH, Besler C, et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation. 2007 ; 116: 163-173
23. Yue WS, Lau KK, Siu CW, et al. Impact of glycemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2011 ; 10: 113-113
24. Wang CH, Ting MK, Verma S, et al. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am Heart J. 2006 ; 152: 1051.e1 - e8
25. Makino H, Okada S, Nagumo A, et al. Pioglitazone treatment stimulates circulating CD34-positive cells in type 2 diabetes patients. Diabetes Res Clin Pract. 2008 ; 81: 327-330
26. Fadini GP, de Kreutzenberg SV, Mariano V, et al. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. Diabetes Obes Metab. 2011 ; 13: 718-725
27. Reinhard H, Jacobsen PK, Lajer M, et al. Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes. Diabetologia. 2010 ; 53: 2129-2133
28. Kusuyama T, Omura T, Nishiya D, et al. Effects of treatment for diabetes mellitus on circulating vascular progenitor cells. J Pharmacol Sci. 2006 ; 102: 96-102
29. Lev EI, Leshem-Lev D, Mager A, et al. Circulating endothelial progenitor cell levels and function in patients who experienced late coronary stent thrombosis. Eur Heart J. 2010 ; 31: 2625-2632
30. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001 ; 103: 2885-2890
31. Chen JZ, Zhu JH, Wang XX, et al. Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood. J Mol Cell Cardiol. 2004 ; 36: 233-239
32. Blann AD, Woywodt A, Bertolini F, et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost. 2005 ; 93: 228-235
33. Woywodt A, Blann AD, Kirsch T, et al. Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol. J Thromb Haemost. 2006 ; 4: 671-677
34. Gallagher KA, Liu ZJ, Xiao M, et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest. 2007 ; 117: 1249-1259
35. Fadini GP, Sartore S, Schiavon M, et al. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia. 2006 ; 49: 3075-3084
36. Fadini GP, Sartore S, Agostinin C, et al. Significance of endothelial progenitor cells in subjects with diabetes. Diabetes Care. 2007 ; 30: 1305-1313
37. Churdchomjan W, Kheolamai P, Manochantr S, et al. Comparison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control. BMC Endocr Disord. 2010 ; 10: 5-5
38. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 ; 329: 977-986
39. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 ; 352: 854-865
40. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011 ; 364: 818-828
41. Wallerstedt E, Smith U, Andersson CX. Protein kinase C-δ is involved in the inflammatory effect of IL-6 in mouse adipose cells. Diabetologia. 2010 ; 53: 946-946